Opsona Therapeutics Ltd. initiates a Phase II Study with OPN-305, a First-in Class Monoclonal Antibody
2013-05-07
- Dublin, Ireland - Opsona Therapeutics Ltd (‘Opsona'), the innate immune drug development company focused on novel therapeutic approaches to treat autoimmune and inflammatory diseases, today announced that it has initiated a phase II clinical trial in renal transplant patients at high risk of delayed graft function with its lead drug candidate OPN-305.
Opsona Therapeutics Limited raises €33 million (USD 43 million) oversubscribed Series C equity financing to advance clinical development of its lead product OPN-305
2013-04-29
- Dublin, Ireland - Opsona Therapeutics Limited (‘Opsona'), the innate immune drug development company, today announced that it has raised €33 million (USD 43 million) in an oversubscribed Series C financing. The participants in this Series C financing include existing investors, Novartis Venture Fund, Fountain Healthcare Partners, Roche Venture Fund and Seroba Kernel Life Sciences. The new investors joining the consortium are BB Biotech Ventures, Sunstone Capital, Baxter Ventures, Amgen Ventures, and EMBL Ventures. BB Biotech Ventures and Novartis Venture Fund led the Series C financing round. BB Biotech Ventures, Sunstone Capital and Baxter Ventures will be joining the board of directors.
Opsona wins Outstanding Achievement Award
2012-07-20
- Opsona Therapeutics was recently recognized for its success in securing research funding receiving an Outstanding Achievement Award at the recent Enterprise Ireland ‘h' event.
Opsona Therapeutics announces the issuance of new patent from the European Patent Office (EPO) covering the development and use of an antibody directed against Toll-like Receptor TLR-2
2012-04-17
- April 17th, 2012, Dublin, Ireland - Opsona Therapeutics, the innate immune drug development company,today announced that the European Patent Office has issued EP Patent 1,664,118 which covers an antibody directed against Toll-like Receptor (TLR-2) and the use and development thereof.
Opsona Appoints Dr Martin Welschof as CEO and Conor Dalton as Director of Finance
2012-02-09
- February 9th, 2012, Dublin, Ireland - Opsona Therapeutics, the innate immune drug development company, today announced that it has appointed two experienced biopharm executives to complement its management team.
Opsona Therapeutics announces initiation of a Phase 1 clinical trial with its lead drug
2011-07-05
- Commenting on this announcement; Bernd R. Seizinger, M.D., Ph.D., Executive Chairman of Opsona Therapeutics said," OPN-305 is a first-in-class antibody against Toll-like- Receptor 2, one of the most promising novel drug targets in the innate immune system. TLR-2 has been linked to an increasing number of major human diseases, including autoimmune diseases, renal ischemia, myocardial infarction, stroke and cancer. This phase 1 study will provide the basis to explore the broad medical and commercial viability and opportunity of OPN- 305 in a variety of indications with unmet medical needs."
Martin Welschof, Opsona:"Inventages had the vision and courage to support Opsona's quest to develop first in class and revolutionary treatment option targeting key structures of the innate immune system."
